346599-62-0

Usage

Uses

Used in Pharmaceutical Industry:
4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one is used as a pharmaceutical intermediate for the development of new drugs due to its potential anti-fungal and anti-tumor properties. Its unique structure and pharmacological activities make it a promising candidate for the creation of innovative therapeutic agents.
Used in Research and Development:
In the field of research and development, 4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one is utilized as a key building block for the synthesis of novel compounds with potential biological activities. Its versatile chemical structure allows for the exploration of new chemical entities that may exhibit beneficial properties for various applications in the life sciences.
Used in Drug Synthesis:
4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one is employed as a starting material in the synthesis of various drug candidates. Its unique heterocyclic structure and functional groups provide a foundation for the development of new chemical entities with potential therapeutic applications.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, 4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one is used as a scaffold for the design and optimization of new molecules with improved pharmacological properties. Its presence in drug candidates can contribute to enhanced potency, selectivity, and pharmacokinetic profiles, ultimately leading to more effective treatments for various diseases and conditions.

InChI:InChI=1/C7H5ClN2O/c8-5-1-2-9-7-4(5)3-6(11)10-7/h1-2H,3H2,(H,9,10,11)

Upstream product

• 346600-25-7 3,3-dibromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one 
• 55052-28-3 4-chloro-7-azaindole 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 74420-18-1 7-Hydroxy-1H-pyrrolo<2,3-b>pyridinium m-chlorobenzoate 
• 271-63-6 7-Azaindole 

Downstream Products

• 956462-75-2 [1-(2,3-dioxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-4-yl]-carbamic acid tert-butyl ester 
• 346600-27-9 5-(4-chloro-2-oxo-1,2-dihydro-pyrrolo [2,3-b]pyridin-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide 
• 1528549-21-4 C₁₃H₁₀FN₃O₂ 
• 956460-59-6 [1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-4-yl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

BIARYL KINASE INHIBITORS

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders.

SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY

The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G (HNCO)f 7 (R )x N * (GP1) (2) GP is a group GP2: 10 (R )r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members; the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and J1, J2, R4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims

PHARMACEUTICAL COMPOUNDS

The invention provides compounds of the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein J1-J2 is CH=CH, N=CH, CH=N, HN-C(O) or CH2CO; T is N or CH and GP is as defined in the claims. The compounds have activity as inhibitors of PKA and PKB kinases and are useful in the treatment of cancers.

PHARMACEUTICAL COMPOUNDS

Compounds of the formula (I), and salts, solvates, tautomers and N-oxide thereof; wherein TG is selected from groups (1) and (2): wherein the asterisk (*) represents the point of attachment of the group E to the group X; Rla is an optionally substituted aryl or heteroaryl group; Rlb is hydrogen or a group Rla; X is an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 are heteroatoms selected from O, N and S; and A, E, R2, R3, R4, Q1 and Q2 are as defined in the claims; provided that when E is aryl or heteroaryl, then Q2 is other than a bond; and further provided that the moiety (a) is other than a group (BG1) or (BG2); wherein (BGl) and (BG2) are each optionally substituted; T is N or CRZ; J1-J2 is selected from N=C(RZ), (RZ)C=N, (RZ)N-C(O), (RZ)2C-C(O), N=N and (RZ)C=C(R6); J4 -J3 is a group N=C(RZ) or a group (RZ)N-CO; and RZ is hydrogen or a substituent. The compounds of the formula (I) have PKA and PKB kinase inhibiting activity and are useful in the treatment of cancers.

4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors

This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention fuirther relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.